Ada Braun
About
Ada Braun is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Ada Braun has authored 63 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 25 papers in Radiology, Nuclear Medicine and Imaging and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ada Braun's work include Bone health and treatments (47 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and Cancer Diagnosis and Treatment (12 papers). Ada Braun is often cited by papers focused on Bone health and treatments (47 papers), Radiopharmaceutical Chemistry and Applications (22 papers) and Cancer Diagnosis and Treatment (12 papers). Ada Braun collaborates with scholars based in United States, Australia and United Kingdom. Ada Braun's co-authors include Alison Stopeck, Allan Lipton, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Roger Dansey, Susie Jun, Jean-Jacques Body, Michelle Fan, Katia Tonkin and Yasuhiro Fujiwara and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.
In The Last Decade
Ada Braun
62 papers receiving 3.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ada Braun United States | 22 | 2.7k | 834 | 754 | 749 | 656 | 63 | 3.2k | ||
| Jean-Jacques Body Belgium | 15 | 2.3k 0.9× | 777 0.9× | 503 0.7× | 706 0.9× | 560 0.9× | 24 | 2.8k | ||
| Michael Rader United States | 9 | 1.8k 0.7× | 463 0.6× | 1.0k 1.3× | 666 0.9× | 422 0.6× | 20 | 2.4k | ||
| Aristotle Bamias Greece | 28 | 1.9k 0.7× | 858 1.0× | 792 1.1× | 189 0.3× | 855 1.3× | 88 | 3.3k | ||
| Lawrence I. Karsh United States | 21 | 1.8k 0.7× | 397 0.5× | 1.8k 2.4× | 783 1.0× | 598 0.9× | 113 | 3.2k | ||
| H.P. Sleeboom Netherlands | 12 | 1.5k 0.6× | 540 0.6× | 405 0.5× | 484 0.6× | 334 0.5× | 21 | 1.8k | ||
| Piotr Milecki Poland | 22 | 1.7k 0.6× | 351 0.4× | 1.3k 1.7× | 853 1.1× | 430 0.7× | 99 | 2.6k | ||
| María Eugenia Ibarrarán Viniegra Argentina | 7 | 1.5k 0.5× | 539 0.6× | 300 0.4× | 420 0.6× | 351 0.5× | 20 | 1.7k | ||
| Richard H. De Boer Australia | 15 | 1.7k 0.6× | 426 0.5× | 669 0.9× | 363 0.5× | 297 0.5× | 48 | 2.1k | ||
| Donna Holloway United States | 12 | 2.1k 0.8× | 1.2k 1.5× | 209 0.3× | 366 0.5× | 257 0.4× | 14 | 2.9k | ||
| Susie Jun United States | 15 | 3.7k 1.4× | 1.2k 1.5× | 1.4k 1.8× | 1.1k 1.4× | 802 1.2× | 25 | 4.9k |
Countries citing papers authored by Ada Braun
Since
Specialization
Citations
This map shows the geographic impact of Ada Braun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ada Braun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ada Braun more than expected).
Fields of papers citing papers by Ada Braun
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ada Braun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ada Braun. The network helps show where Ada Braun may publish in the future.
Co-authorship network of co-authors of Ada Braun
This figure shows the co-authorship network connecting the top 25 collaborators of Ada Braun. A scholar is included among the top collaborators of Ada Braun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ada Braun. Ada Braun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Engellau, Jacob, Leanne L. Seeger, R. J. Grimer, et al.. (2018). Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone. World Journal of Surgical Oncology. 16(1). 191–191.
2.
Raje, Noopur, Saroj Vadhan‐Raj, Wolfgang Willenbacher, et al.. (2016). Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial. Blood Cancer Journal. 6(1). e378–e378.
3.
Braun, Ada, Walburga Engel-Riedel, Folker Schneller, et al.. (2015). Efficacy and Safety of Imprime Pgg, a Novel Innate Immune Modulator, in Combination with Bevacizumab (BEV), Carboplatin and Paclitaxel for the 1St-Line Treatment of Stage Iv Nsclc. Annals of Oncology. 26. i29–i29.
4.
Body, Jean-Jacques, Henry G. Bone, Richard H. De Boer, et al.. (2015). Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European Journal of Cancer. 51(13). 1812–1821.
5.
Venepalli, Neeta K., Howard Ozer, Yang Lü, et al.. (2015). Phase Ib study of PGG beta glucan in combination with anti-MUC1 antibody (BTH1704) and gemcitabine for the treatment of advanced pancreatic cancer.. Journal of Clinical Oncology. 33(3_suppl). TPS493–TPS493.
6.
Stopeck, Alison, Karim Fizazi, Jean-Jacques Body, et al.. (2015). Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive Care in Cancer. 24(1). 447–455.
7.
Diel, Ingo, Jean‐Jacques Body, Alison Stopeck, et al.. (2015). The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. European Journal of Cancer. 51(11). 1467–1475.
8.
Smith, Mitchell R., Robert E. Coleman, Laurence Klotz, et al.. (2014). Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology. 26(2). 368–374.
9.
Martín‐Broto, Javier, Charles S. Cleeland, Paul Glare, et al.. (2014). Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. Acta Oncologica. 53(9). 1173–1179.
10.
Block, Geoffrey A., Ogo Egbuna, Steven Zeig, et al.. (2014). The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study.. Journal of Clinical Oncology. 32(15_suppl). e20649–e20649.
11.
Matza, Louis S., Karen Chung, Kate Van Brunt, et al.. (2013). Health state utilities for skeletal-related events secondary to bone metastases. The European Journal of Health Economics. 15(1). 7–18.
12.
Goss, Paul E., Carlos H. Barrios, Arlene Chan, et al.. (2013). Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.. Journal of Clinical Oncology. 31(15_suppl). TPS662–TPS662.
13.
Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092.
14.
Fallowfield, Lesley, Roger von Moos, Luís Costa, et al.. (2012). Weighing Bone-targeted Treatment Options for Patients with Solid Tumours and Skeletal Complications from Metastatic Disease. European Oncology & Haematology. 8(3). 148–148.
15.
Goessl, Carsten, Leonid Katz, William C. Dougall, et al.. (2012). The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction. Annals of the New York Academy of Sciences. 1263(1). 29–40.
16.
Stopeck, Alison, Allan Lipton, Jean-Jacques Body, et al.. (2010). Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. Journal of Clinical Oncology. 28(35). 5132–5139.
17.
Stopeck, Alison, Miguel Martín, Diana Ritchie, et al.. (2010). Abstract P6-14-01: Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase. Cancer Research. 70(24_Supplement). P6–14.
18.
Ray, Kevin C., Stacy A. Blaine, M. Kay Washington, et al.. (2009). Transmembrane and Soluble Isoforms of Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulate Distinct Processes in the Pancreas. Gastroenterology. 137(5). 1785–1794.
19.
Braun, Ada, et al.. (2005). The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anti-Cancer Drugs. 16(10). 1099–1108.
20.
Braun, Ada, W. Achterrath, H. Wilke, et al.. (2004). New systemic frontline treatment for metastatic colorectal carcinoma. Cancer. 100(8). 1558–1577.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jean-Jacques Body Breakdown of academic impact, for papers by Michael Rader Breakdown of academic impact, for papers by Aristotle Bamias Breakdown of academic impact, for papers by Lawrence I. Karsh Breakdown of academic impact, for papers by H.P. Sleeboom Breakdown of academic impact, for papers by Piotr Milecki Breakdown of academic impact, for papers by María Eugenia Ibarrarán Viniegra Breakdown of academic impact, for papers by Richard H. De Boer Breakdown of academic impact, for papers by Donna Holloway Breakdown of academic impact, for papers by Susie Jun